Journal of Peking University (Health Sciences) ›› 2021, Vol. 53 ›› Issue (5): 921-927. doi: 10.19723/j.issn.1671-167X.2021.05.018
Previous Articles Next Articles
GAO Wei-bo,SHI Mao-jing,ZHANG Hai-yan,WU Chun-bo(),ZHU Ji-hong
CLC Number:
[1] |
Alkhateeb AA, Connor JR. The significance of ferritin in cancer: Anti-oxidation, inflammation and tumorigenesis [J]. Biochim Biophys Acta, 2013, 1836(2):245-254.
doi: 10.1016/j.bbcan.2013.07.002 pmid: 23891969 |
[2] | Moore C, Ormseth M, Fuchs H. Causes and significance of markedly elevated serum ferritin levels in an academic medical center [J]. J Clin Rhuematol, 2013, 19(6):324-328. |
[3] |
Crook MA, Walker PLC. Extreme hyperferritinaemia: Clinical causes [J]. J Clin Pathol, 2013, 66(5):438-440.
doi: 10.1136/jclinpath-2012-201090 |
[4] |
Sackett K, Cunderlik M, Sahni N, et al. Extreme hyperferritinemia: Causes and impact on diagnostic reasoning [J]. Am J Clin Pathol, 2016, 145(5):646-650.
doi: 10.1093/ajcp/aqw053 pmid: 27247369 |
[5] |
Otrock ZK, Hock KG, Riley SB, et al. Elevated serum ferritin is not specific for hemophagocytic lymphohistiocytosis [J]. Ann Hematol, 2017, 96(10):1667-1672.
doi: 10.1007/s00277-017-3072-0 pmid: 28762079 |
[6] |
Allen CE, Yu X, Kozinetz CA, et al. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis [J]. Pediatr Blood Cancer, 2008, 50(6):1227-1235.
pmid: 18085676 |
[7] |
Zandman-Goddard G, Shoenfeld Y. Hyperferritinemia in autoimmunity [J]. Isr Med Assoc J, 2008, 10(1):83-84.
pmid: 18300583 |
[8] |
Zandman-Goddard G, Orbach H, Agmon-Levin N, et al. Hyperferritinemia is associated with serologic antiphospholipid syndrome in SLE patients [J]. Clin Rev Allergy Immunol, 2013, 44(1):23-30.
doi: 10.1007/s12016-011-8264-0 |
[9] |
Rosário C, Zandman-Goddard G, Meyron-Holtz EG, et al. The hyperferritinemic syndrome: Macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome [J]. BMC Med, 2013, 11:185.
doi: 10.1186/1741-7015-11-185 |
[10] |
Evensen KJ, Swaak TJG, Nossent JC. Increased ferritin response in adult Still’s disease: Specificity and relationship to outcome [J]. Scand J Rheumatol, 2007, 36(2):107-110.
pmid: 17476616 |
[11] |
Lee MH, Means RT Jr. Extremely elevated serum ferritin levels in a university hospital: Associated diseases and clinical significance [J]. Am J Med, 1995, 98(6):566-571.
pmid: 7778572 |
[12] |
Orbach H, Zandman-Goddard G, Amital H, et al. Novel bio-markers in autoimmune diseases: Prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases [J]. Ann N Y Acad Sci, 2007, 1109:385-400.
doi: 10.1196/annals.1398.044 |
[13] |
Agmon-Levin N, Rosário C, Katz BSP, et al. Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS) [J]. Lupus, 2013, 22(13):1327-1335.
doi: 10.1177/0961203313504633 pmid: 24036580 |
[14] | Wang W, Knovich MA, Coffman LG, et al. Serum ferritin: Past, present and future [J]. Biochem Biophys Acta, 2010, 1800(8):760-769. |
[15] |
Crook MA. Hyperferritinaemia: Laboratory implications [J]. Ann Clin Biochem, 2012, 49(Pt 3):211-213.
doi: 10.1258/acb.2012.012059 pmid: 22550325 |
[16] | Kernan KF, Carcillo JA. Hyperferritinemia and inflammation [J]. Int Immumol, 2017, 29(9):401-409. |
[17] |
Tothova Z, Berliner N. hemophagocytic syndrome and critical illness: New insights into diagnosis and management [J]. J Intensive Care Med, 2015, 30(7):401-412.
doi: 10.1177/0885066613517076 pmid: 24407034 |
[18] |
Chandrakasan S, Filipovich AH. Hemophagocytic lymphohistiocytosis: Advances in pathophysiology, diagnosis, and treatment [J]. J Pediatr, 2013, 163(5):1253-1259.
doi: 10.1016/j.jpeds.2013.06.053 |
[19] | Jordan MB, Allen CE, Weitzman S, et al. How I treat hemo-phagocytic lymphohistiocytosis [J]. Blood, 2011, 118(15):4041-4052. |
[20] |
Henter JI, Elinder G, Ost A. The FHL Study Group of the Histiocyte Society. Diagnostic guidelines for hemophagocytic lymphohistiocytosis [J]. Semin Oncol, 1991, 18(1):29-33.
pmid: 1992521 |
[21] |
Henter JI, Samuelsson-Horne A, Aricò M, et al. Histocyte Society. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation [J]. Blood, 2002, 100(7):2367-2373.
doi: 10.1182/blood-2002-01-0172 |
[22] |
Henter JI, Samuelsson-Horne A, Aricò M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis [J]. Pediatr Blood Cancer, 2007, 48(2):124-131.
doi: 10.1002/(ISSN)1545-5017 |
[23] |
Janka GE, Lehmberg K. Hemophagocytic syndromes-an update [J]. Blood Rev, 2014, 28(4):135-142.
doi: 10.1016/j.blre.2014.03.002 |
[24] |
Senjo H, Higuchi T, Okada S, et al. Hyperferritinemia: Causes and significance in a general hospital [J]. Hematology, 2018, 23(10):817-822.
doi: 10.1080/10245332.2018.1488569 |
[25] |
Kaito K, Kobayashi M, Katayama T, et al. Prognostic factors of hemophagocytic syndrome in adults: analysis of 34 cases [J]. Eur J Haematol, 1997, 59(4):247-253.
pmid: 9338623 |
[26] |
Janka GE, Schneider EM. Modern management of children with haemophagocytic Lymphohistiocytosis [J]. Br J Haematol, 2004, 124(1):4-14.
doi: 10.1046/j.1365-2141.2003.04726.x |
[27] | 金志丽, 王旖旎, 胡亮钉, 等. 血清铁蛋白升高在成人噬血细胞综合征诊断中的作用 [J]. 临床血液学杂志, 2016, 29(9):717-720. |
[28] |
Schram AM, Campigotto F, Mullally A, et al. Marked hyperferritinemia does not predict for HLH in the adult population [J]. Blood, 2015, 125(10):1548-1552.
doi: 10.1182/blood-2014-10-602607 |
[1] | Junyong OU,Kunming NI,Lulin MA,Guoliang WANG,Ye YAN,Bin YANG,Gengwu LI,Haodong SONG,Min LU,Jianfei YE,Shudong ZHANG. Prognostic factors of patients with muscle invasive bladder cancer with intermediate-to-high risk prostate cancer [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 582-588. |
[2] | Shuai LIU,Lei LIU,Zhuo LIU,Fan ZHANG,Lulin MA,Xiaojun TIAN,Xiaofei HOU,Guoliang WANG,Lei ZHAO,Shudong ZHANG. Clinical treatment and prognosis of adrenocortical carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 624-630. |
[3] | Le YU,Shaohui DENG,Fan ZHANG,Ye YAN,Jianfei YE,Shudong ZHANG. Clinicopathological characteristics and prognosis of multilocular cystic renal neoplasm of low malignant potential [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 661-666. |
[4] | Zezhen ZHOU,Shaohui DENG,Ye YAN,Fan ZHANG,Yichang HAO,Liyuan GE,Hongxian ZHANG,Guoliang WANG,Shudong ZHANG. Predicting the 3-year tumor-specific survival in patients with T3a non-metastatic renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 673-679. |
[5] | Yangyi FANG,Qiang LI,Zhigao HUANG,Min LU,Kai HONG,Shudong ZHANG. Well-differentiated papillary mesothelial tumour of the tunica vaginalis: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 741-744. |
[6] | Yuanyuan ZENG,Yun XIE,Daonan CHEN,Ruilan WANG. Related factors of euthyroid sick syndrome in patients with sepsis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 526-532. |
[7] | Jian-bin LI,Meng-na LYU,Qiang CHI,Yi-lin PENG,Peng-cheng LIU,Rui WU. Early prediction of severe COVID-19 in patients with Sjögren’s syndrome [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1007-1012. |
[8] | Hai-hong YAO,Fan YANG,Su-mei TANG,Xia ZHANG,Jing HE,Yuan JIA. Clinical characteristics and diagnostic indicators of macrophage activation syndrome in patients with systemic lupus erythematosus and adult-onset Still's disease [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 966-974. |
[9] | Huan-rui LIU,Xiang PENG,Sen-lin LI,Xin GOU. Risk modeling based on HER-2 related genes for bladder cancer survival prognosis assessment [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 793-801. |
[10] | Zi-xuan XUE,Shi-ying TANG,Min QIU,Cheng LIU,Xiao-jun TIAN,Min LU,Jing-han DONG,Lu-lin MA,Shu-dong ZHANG. Clinicopathologic features and prognosis of young renal tumors with tumor thrombus [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 802-811. |
[11] | Han LU,Jian-yun ZHANG,Rong YANG,Le XU,Qing-xiang LI,Yu-xing GUO,Chuan-bin GUO. Clinical factors affecting the prognosis of lower gingival squamous cell carcinoma [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 702-707. |
[12] | Yun-fei SHI,Hao-jie WANG,Wei-ping LIU,Lan MI,Meng-ping LONG,Yan-fei LIU,Yu-mei LAI,Li-xin ZHOU,Xin-ting DIAO,Xiang-hong LI. Analysis of clinicopathological and molecular abnormalities of angioimmunoblastic T-cell lymphoma [J]. Journal of Peking University (Health Sciences), 2023, 55(3): 521-529. |
[13] | Xiao-juan ZHU,Hong ZHANG,Shuang ZHANG,Dong LI,Xin LI,Ling XU,Ting LI. Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 243-253. |
[14] | Yu-mei LAI,Zhong-wu LI,Huan LI,Yan WU,Yun-fei SHI,Li-xin ZHOU,Yu-tong LOU,Chuan-liang CUI. Clinicopathological features and prognosis of anorectal melanoma: A report of 68 cases [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 262-269. |
[15] | Qi SHEN,Yi-xiao LIU,Qun HE. Mucinous tubular and spindle cell carcinoma of kidney: Clinicopathology and prognosis [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 276-282. |
|